|
A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma. |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Genentech/Roche; Lilly; Merck; Novartis; Pfizer |
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst) |
|
|
Honoraria - Abbvie; Bayer; Bristol-Myers Squibb Japan; EA Pharma; Eisai; Gilead Sciences; Merck Serono; Merck Serono; MSD; Novartis; Pfizer; Taiho Pharmaceutical |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; MSD |
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst) |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Novartis |
Research Funding - Bayer (Inst); BTG (Inst); Ipsen (Inst) |
|
|
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; Delcath Systems; Lilly; MSD; Novartis; Roche; Sanofi |
Consulting or Advisory Role - Amgen; Baxalta; Bayer; Delcath Systems; Lilly; Novartis; Roche |
Research Funding - Novartis |
Travel, Accommodations, Expenses - Bayer; Ipsen; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - BeiGene; Roche |
Stock and Other Ownership Interests - Aurinia Pharmaceuticals; BeiGene; Roche; Savient; Teva |
|
|
|
|
|
|
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Lilly; Merck; Novartis; Sanofi |
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst) |